Efficacy and Safety of Vitamin K-Antagonists (VKA) for Atrial Fibrillation in Non-Dialysis Dependent Chronic Kidney Disease
出版年份 2014 全文链接
标题
Efficacy and Safety of Vitamin K-Antagonists (VKA) for Atrial Fibrillation in Non-Dialysis Dependent Chronic Kidney Disease
作者
关键词
-
出版物
PLoS One
Volume 9, Issue 5, Pages e94420
出版商
Public Library of Science (PLoS)
发表日期
2014-05-10
DOI
10.1371/journal.pone.0094420
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Renal Impairment in a “Real-Life” Cohort of Anticoagulated Patients With Atrial Fibrillation (Implications for Thromboembolism and Bleeding)
- (2013) Vanessa Roldán et al. AMERICAN JOURNAL OF CARDIOLOGY
- Stroke Prevention in Atrial Fibrillation Patients With Chronic Kidney Disease
- (2013) Robert G. Hart et al. CANADIAN JOURNAL OF CARDIOLOGY
- More Evidence on an Abominable Pairing
- (2013) Wolfgang C. Winkelmayer CIRCULATION
- Betrixaban compared with warfarin in patients with atrial fibrillation: results of a phase 2, randomized, dose-ranging study (Explore-Xa)
- (2013) S. J. Connolly et al. EUROPEAN HEART JOURNAL
- The clinical evaluation of International Normalized Ratio variability and control in conventional oral anticoagulant administration by use of the variance growth rate
- (2013) S. Ibrahim et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
- Estimated glomerular filtration rate is associated with major bleeding complications but not thromboembolic events, in anticoagulated patients taking warfarin
- (2013) Mattias Wieloch et al. THROMBOSIS RESEARCH
- An Update on the Prognosis of Patients With Atrial Fibrillation
- (2012) David D. McManus et al. CIRCULATION
- 2012 focused update of the ESC Guidelines for the management of atrial fibrillation
- (2012) et al. EUROPACE
- Stroke and Bleeding in Atrial Fibrillation with Chronic Kidney Disease
- (2012) Jonas Bjerring Olesen et al. NEW ENGLAND JOURNAL OF MEDICINE
- Warfarin in Atrial Fibrillation Patients with Moderate Chronic Kidney Disease
- (2011) R. G. Hart et al. Clinical Journal of the American Society of Nephrology
- Chronic Kidney Disease in Patients with Ischemic Stroke
- (2011) Yuuko Tsukamoto et al. Journal of Stroke & Cerebrovascular Diseases
- Incidence of chronic kidney disease in patients with atrial fibrillation and its relevance for prescribing new oral antithrombotic drugs
- (2011) J. KOOIMAN et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
- Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: Improving Global Outcomes (KDIGO)
- (2011) Charles A. Herzog et al. KIDNEY INTERNATIONAL
- Apixaban versus Warfarin in Patients with Atrial Fibrillation
- (2011) Christopher B. Granger et al. NEW ENGLAND JOURNAL OF MEDICINE
- Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation
- (2011) Manesh R. Patel et al. NEW ENGLAND JOURNAL OF MEDICINE
- Methods to evaluate renal function in elderly patients: a systematic literature review
- (2010) G. Van Pottelbergh et al. AGE AND AGEING
- Patient Outcomes after Acute Pulmonary Embolism
- (2009) Frederikus A. Klok et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- Anemia, hypoalbuminemia, and renal impairment as predictors of bleeding complications in patients receiving anticoagulation therapy for nonvalvular atrial fibrillation: A secondary analysis
- (2009) Ahmed H. Abdelhafiz et al. CLINICAL THERAPEUTICS
- Dabigatran versus Warfarin in Patients with Atrial Fibrillation
- (2009) Stuart J. Connolly et al. NEW ENGLAND JOURNAL OF MEDICINE
- INR variability in atrial fibrillation: A risk model for cerebrovascular events
- (2008) Philippe Amouyel et al. European Journal of Internal Medicine
- Prediction of hemorrhagic and thrombotic events in patients with mechanical heart valve prostheses treated with oral anticoagulants
- (2008) Y. VAN LEEUWEN et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started